Leadership/Faculty/Staff
Research Programs
Clinical Trials/Studies
Referral Information
Travel/Local Information
Support Programs/Services
Educational Programs
The Power of Giving
Make a Donation
Online Shopping
Fundraising Events
Faces of Hope
Journey of Hope
Voices of Hope
Family Scrapbook
Mission and History
Careers
Board of Advisors
Community Partners
In the News
|
 |
James J. Vredenburgh, MD
Medical Director, Adult Clinical Services
Professor of Medicine
Duke University Medical Center
DUMC Box 3624
Durham, NC 27710
Tel: (919) 668-2993
Fax: (919) 684-6674
Email: vrede001@mc.duke.edu |
Dr. Vredenburgh is board certified in Medical Oncology and Hematology, and has worked in the Division of Medical Oncology at Duke for 12 years. He joined the Center in January, 2003. His primary focus is patient care, and his clinical research interests focus on primary brain tumors as well as brain metastases. Additional clinical research efforts focus on complications of therapy.
Dr. Vredenburgh's CV
Recent Publications:
Everson RG,Graner MW,Gromeier M,Vredenburgh JJ,Desjardins A,Reardon DA,Friedman HS,Friedman AH,Bigner DD,Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.,May 01,2008, (717-32) - Expert review of anticancer therapy Abstract [More ...]
Choi JD,Powers CJ,Vredenburgh JJ,Friedman AH,Sampson JH. Cryptococcal meningitis in patients with glioma: a report of two cases.,Apr 09,2008, (-) - Journal of neuro-oncology Abstract [More ...]
Reardon DA,Wen PY,Desjardins A,Batchelor TT,Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.,Apr 01,2008, (541-553) - Expert opinion on biological therapy Abstract [More ...]
Reardon DA,Desjardins A,Vredenburgh JJ,Sathornsumetee S,Rich JN,Quinn JA,Lagattuta TF,Egorin MJ,Gururangan S,McLendon R,Herndon Ii JE,Friedman AH,Salvado AJ,Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma.,Mar 21,2008, (-) - Neuro-oncology Abstract [More ...]
Reardon DA,Zalutsky MR,Akabani G,Coleman RE,Friedman AH,Herndon JE 2nd,McLendon RE,Pegram CN,Quinn JA,Rich JN,Vredenburgh JJ,Desjardins A,Guruangan S,Boulton S,Raynor RH,Dowell JM,Wong TZ,Zhao XG,Friedman HS,Bigner DD. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.,Feb 20,2008, (-) - Neuro-oncology Abstract [More ...]
Reardon DA,Desjardins A,Rich JN,Vredenburgh JJ. The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma.,Feb 07,2008, (-) - Current treatment options in oncology Abstract [More ...]
Sathornsumetee S,Cao Y,Marcello JE,Herndon JE 2nd,McLendon RE,Desjardins A,Friedman HS,Dewhirst MW,Vredenburgh JJ,Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.,Jan 10,2008, (271-8) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]
Vredenburgh JJ,Desjardins A,Herndon JE 2nd,Marcello J,Reardon DA,Quinn JA,Rich JN,Sathornsumetee S,Gururangan S,Sampson J,Wagner M,Bailey L,Bigner DD,Friedman AH,Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.,Oct 20,2007, (4722-9) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]
Badruddoja MA,Keir ST,King I,Zeidner J,Vredenburgh JJ,Muhlbaier LH,Bigner DD,Friedman HS. Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.,May 23,2007, (-) - Neuro-oncology Abstract [More ...]
Sathornsumetee S,Reardon DA,Desjardins A,Quinn JA,Vredenburgh JJ,Rich JN. Molecularly targeted therapy for malignant glioma.,May 22,2007, (-) - Cancer Abstract [More ...] |
NOTE: For more publications on this researcher, please visit Pubmed - A service of the National Library of Medicine and the National Institutes of Health.
Back to top
|
|
DUKEHEALTH.ORG
Duke UNIVERSITY
